Question 1

Does NewEdge Advisors own OCUL stock?

Accepted Answer

Yes. As of its Q2 2026 13F, NewEdge Advisors holds 16,725 shares of OCUL (Ocular Therapeutix), worth $164,240.

Question 2

How many shares of OCUL does NewEdge Advisors own?

Accepted Answer

As of its Q2 2026 13F, NewEdge Advisors holds 16,725 shares of OCUL (Ocular Therapeutix).

Question 3

What is NewEdge Advisors' OCUL position worth?

Accepted Answer

As of its Q2 2026 13F, NewEdge Advisors' OCUL position is worth $164,240.

Question 4

Is NewEdge Advisors buying or selling OCUL?

Accepted Answer

In Q2 2026, NewEdge Advisors increased its OCUL position by 2,979 shares (+21.7%).

Question 5

When did NewEdge Advisors first buy OCUL?

Accepted Answer

NewEdge Advisors already held OCUL in its Q4 2018 13F, the earliest on record, and has listed it in 30 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	16,725	+21.7%	$164,240	0.0%	$9.82	27
2026-Q1	Increased	13,746	+1274.6%	$116,429	0.0%	$8.47	35
2025-Q4	Unchanged	1,000	0.0%	$12,140	0.0%	$12.14	0
2025-Q3	Decreased	1,000	-32.4%	$11,690	0.0%	$11.69	0
2025-Q2	Unchanged	1,480	0.0%	$13,734	0.0%	$9.28	0
2025-Q1	Unchanged	1,480	0.0%	$10,848	0.0%	$7.33	0
2024-Q4	Unchanged	1,480	0.0%	$12,639	0.0%	$8.54	0
2024-Q3	Unchanged	1,480	0.0%	$12,876	0.0%	$8.70	0